Table of Contents 1 Market Overview 1.1 Heterozygous Familial Hypercholesterolemia Drug Introduction 1.2 Market Analysis by Type 1.2.1 Overview: Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Type: 2015 VS 2019 VS 2025 1.2.2 Gemcabene Calcium 1.2.3 MGL-3196 1.2.4 ST-103 1.2.5 Others 1.3 Market Analysis by Application 1.3.1 Overview: Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Application: 2015 VS 2019 VS 2025 1.3.2 Clinic 1.3.3 Hospital 1.3.4 Others 1.4 Overview of Global Heterozygous Familial Hypercholesterolemia Drug Market 1.4.1 Global Heterozygous Familial Hypercholesterolemia Drug Market Status and Outlook (2015-2025) 1.4.2 North America (United States, Canada and Mexico) 1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy) 1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) 1.4.5 South America, Middle East & Africa 1.5 Market Dynamics 1.5.1 Market Opportunities 1.5.2 Market Risk 1.5.3 Market Driving Force 2 Manufacturers Profiles 2.1 Daewoong Co Ltd 2.1.1 Daewoong Co Ltd Details 2.1.2 Daewoong Co Ltd Major Business and Total Revenue (Financial Highlights) Analysis 2.1.3 Daewoong Co Ltd SWOT Analysis 2.1.4 Daewoong Co Ltd Product and Services 2.1.5 Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019) 2.2 Madrigal Pharmaceuticals Inc 2.2.1 Madrigal Pharmaceuticals Inc Details 2.2.2 Madrigal Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis 2.2.3 Madrigal Pharmaceuticals Inc SWOT Analysis 2.2.4 Madrigal Pharmaceuticals Inc Product and Services 2.2.5 Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019) 2.3 Esperion Therapeutics Inc 2.3.1 Esperion Therapeutics Inc Details 2.3.2 Esperion Therapeutics Inc Major Business and Total Revenue (Financial Highlights) Analysis 2.3.3 Esperion Therapeutics Inc SWOT Analysis 2.3.4 Esperion Therapeutics Inc Product and Services 2.3.5 Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019) 2.4 Gemphire Therapeutics Inc 2.4.1 Gemphire Therapeutics Inc Details 2.4.2 Gemphire Therapeutics Inc Major Business and Total Revenue (Financial Highlights) Analysis 2.4.3 Gemphire Therapeutics Inc SWOT Analysis 2.4.4 Gemphire Therapeutics Inc Product and Services 2.4.5 Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019) 3 Sales, Revenue and Market Share by Manufacturer 3.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales and Market Share by Manufacturer (2018-2019) 3.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue and Market Share by Manufacturer (2018-2019) 3.3 Market Concentration Rate 3.3.1 Top 3 Heterozygous Familial Hypercholesterolemia Drug Manufacturer Market Share in 2019 3.3.2 Top 6 Heterozygous Familial Hypercholesterolemia Drug Manufacturer Market Share in 2019 3.4 Market Competition Trend 4 Global Market Analysis by Regions 4.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales, Revenue and Market Share by Regions 4.1.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales and Market Share by Regions (2015-2020) 4.1.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue and Market Share by Regions (2015-2020) 4.2 North America Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 4.3 Europe Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 4.4 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 4.5 South America Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 4.6 Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 5 North America by Country 5.1 North America Heterozygous Familial Hypercholesterolemia Drug Sales, Revenue and Market Share by Country 5.1.1 North America Heterozygous Familial Hypercholesterolemia Drug Sales and Market Share by Country (2015-2020) 5.1.2 North America Heterozygous Familial Hypercholesterolemia Drug Revenue and Market Share by Country (2015-2020) 5.2 United States Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 5.3 Canada Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 5.4 Mexico Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 6 Europe by Country 6.1 Europe Heterozygous Familial Hypercholesterolemia Drug Sales, Revenue and Market Share by Country 6.1.1 Europe Heterozygous Familial Hypercholesterolemia Drug Sales and Market Share by Country (2015-2020) 6.1.2 Europe Heterozygous Familial Hypercholesterolemia Drug Revenue and Market Share by Country (2015-2020) 6.2 Germany Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 6.3 UK Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 6.4 France Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 6.5 Russia Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 6.6 Italy Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 7 Asia-Pacific by Regions 7.1 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales, Revenue and Market Share by Regions 7.1.1 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales and Market Share by Regions (2015-2020) 7.1.2 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue and Market Share by Regions (2015-2020) 7.2 China Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 7.3 Japan Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 7.4 Korea Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 7.5 India Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 7.6 Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 7.7 Australia Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 8 South America by Country 8.1 South America Heterozygous Familial Hypercholesterolemia Drug Sales, Revenue and Market Share by Country 8.1.1 South America Heterozygous Familial Hypercholesterolemia Drug Sales and Market Share by Country (2015-2020) 8.1.2 South America Heterozygous Familial Hypercholesterolemia Drug Revenue and Market Share by Country (2015-2020) 8.2 Brazil Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 8.3 Argentina Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 9 Middle East & Africa by Countries 9.1 Middle East & Africa Heterozygous Familial Hypercholesterolemia Drug Sales, Revenue and Market Share by Country 9.1.1 Middle East & Africa Heterozygous Familial Hypercholesterolemia Drug Sales and Market Share by Country (2015-2020) 9.1.2 Middle East & Africa Heterozygous Familial Hypercholesterolemia Drug Revenue and Market Share by Country (2015-2020) 9.2 Saudi Arabia Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 9.3 Turkey Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 9.4 Egypt Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 9.5 South Africa Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) 10 Market Segment by Type 10.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales and Market Share by Type (2015-2020) 10.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue and Market Share by Type (2015-2020) 10.3 Global Heterozygous Familial Hypercholesterolemia Drug Price by Type (2015-2020) 11 Global Heterozygous Familial Hypercholesterolemia Drug Market Segment by Application 11.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application (2015-2020) 11.2 Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Application (2015-2020) 11.3 Global Heterozygous Familial Hypercholesterolemia Drug Price by Application (2015-2020) 12 Market Forecast 12.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales, Revenue and Growth Rate (2021-2025) 12.2 Heterozygous Familial Hypercholesterolemia Drug Market Forecast by Regions (2021-2025) 12.2.1 North America Heterozygous Familial Hypercholesterolemia Drug Market Forecast (2021-2025) 12.2.2 Europe Heterozygous Familial Hypercholesterolemia Drug Market Forecast (2021-2025) 12.2.3 Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Market Forecast (2021-2025) 12.2.4 South America Heterozygous Familial Hypercholesterolemia Drug Market Forecast (2021-2025) 12.2.5 Middle East & Africa Heterozygous Familial Hypercholesterolemia Drug Market Forecast (2021-2025) 12.3 Heterozygous Familial Hypercholesterolemia Drug Market Forecast by Type (2021-2025) 12.3.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Type (2021-2025) 12.3.2 Global Heterozygous Familial Hypercholesterolemia Drug Market Share Forecast by Type (2021-2025) 12.4 Heterozygous Familial Hypercholesterolemia Drug Market Forecast by Application (2021-2025) 12.4.1 Global Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Application (2021-2025) 12.4.2 Global Heterozygous Familial Hypercholesterolemia Drug Market Share Forecast by Application (2021-2025) 13 Sales Channel, Distributors, Traders and Dealers 13.1 Sales Channel 13.1.1 Direct Marketing 13.1.2 Indirect Marketing 13.2 Distributors, Traders and Dealers 14 Research Findings and Conclusion 15 Appendix 15.1 Methodology 15.2 Data Source 15.3 Disclaimer 15.4 About US

List of Tables Table 1. Global Heterozygous Familial Hypercholesterolemia Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025 Table 2. Breakdown of Heterozygous Familial Hypercholesterolemia Drug by Company Type (Tier 1, Tier 2 and Tier 3) Table 3. Global Heterozygous Familial Hypercholesterolemia Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025 Table 4. Market Opportunities in Next Few Years Table 5. Market Risks Analysis Table 6. Market Drivers Table 7. Daewoong Co Ltd Basic Information, Manufacturing Base and Competitors Table 8. Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Major Business Table 9. Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Total Revenue (USD Million) (2017-2018) Table 10. Daewoong Co Ltd SWOT Analysis Table 11. Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Product and Services Table 12. Daewoong Co Ltd Heterozygous Familial Hypercholesterolemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019) Table 13. Madrigal Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors Table 14. Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Major Business Table 15. Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Total Revenue (USD Million) (2017-2018) Table 16. Madrigal Pharmaceuticals Inc SWOT Analysis Table 17. Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Product and Services Table 18. Madrigal Pharmaceuticals Inc Heterozygous Familial Hypercholesterolemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019) Table 19. Esperion Therapeutics Inc Basic Information, Manufacturing Base and Competitors Table 20. Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Major Business Table 21. Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Total Revenue (USD Million) (2017-2018) Table 22. Esperion Therapeutics Inc SWOT Analysis Table 23. Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Product and Services Table 24. Esperion Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019) Table 25. Gemphire Therapeutics Inc Basic Information, Manufacturing Base and Competitors Table 26. Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Major Business Table 27. Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Total Revenue (USD Million) (2017-2018) Table 28. Gemphire Therapeutics Inc SWOT Analysis Table 29. Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Product and Services Table 30. Gemphire Therapeutics Inc Heterozygous Familial Hypercholesterolemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019) Table 31. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Manufacturer (2018-2019) (K Pcs) Table 32. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Manufacturer (2018-2019) (USD Million) Table 33. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Regions (2015-2020) (K Pcs) Table 34. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Regions (2015-2020) Table 35. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Regions (2015-2020) (USD Million) Table 36. North America Heterozygous Familial Hypercholesterolemia Drug Sales by Countries (2015-2020) (K Pcs) Table 37. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Countries (2015-2020) Table 38. North America Heterozygous Familial Hypercholesterolemia Drug Revenue by Countries (2015-2020) (USD Million) Table 39. North America Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Countries (2015-2020) Table 40. Europe Heterozygous Familial Hypercholesterolemia Drug Sales by Countries (2015-2020) (K Pcs) Table 41. Europe Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Countries (2015-2020) Table 42. Europe Heterozygous Familial Hypercholesterolemia Drug Revenue by Countries (2015-2020) (USD Million) Table 43. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales by Regions (2015-2020) (K Pcs) Table 44. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Regions (2015-2020) Table 45. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue by Regions (2015-2020) (USD Million) Table 46. South America Heterozygous Familial Hypercholesterolemia Drug Sales by Countries (2015-2020) (K Pcs) Table 47. South America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Countries (2015-2020) Table 48. South America Heterozygous Familial Hypercholesterolemia Drug Revenue by Countries (2015-2020) (USD Million) Table 49. South America Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Countries (2015-2020) Table 50. Middle East & Africa Heterozygous Familial Hypercholesterolemia Drug Sales by Countries (2015-2020) (K Pcs) Table 51. Middle East & Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Countries (2015-2020) Table 52. Middle East & Africa Heterozygous Familial Hypercholesterolemia Drug Revenue by Countries (2015-2020) (USD Million) Table 53. Middle East & Africa Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Countries (2015-2020) Table 54. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Type (2015-2020) (K Pcs) Table 55. Global Heterozygous Familial Hypercholesterolemia Drug Sales Share by Type (2015-2020) Table 56. Global Heterozygous Familial Hypercholesterolemia Drug Revenue by Type (2015-2020) (USD Million) Table 57. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Share by Type (2015-2020) Table 58. Global Heterozygous Familial Hypercholesterolemia Drug Sales by Application (2015-2020) (K Pcs) Table 59. Global Heterozygous Familial Hypercholesterolemia Drug Sales Share by Application (2015-2020) Table 60. Global Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Regions (2021-2025) (K Pcs) Table 61. Global Heterozygous Familial Hypercholesterolemia Drug Market Share Forecast by Regions (2021-2025) Table 62. Global Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Type (2021-2025) (K Pcs) Table 63. Global Heterozygous Familial Hypercholesterolemia Drug Market Share Forecast by Type (2021-2025) Table 64. Global Heterozygous Familial Hypercholesterolemia Drug Sales Forecast by Application (2021-2025) Table 65. Global Heterozygous Familial Hypercholesterolemia Drug Market Share Forecast by Application (2021-2025) Table 66. Direct Channel Pros & Cons Table 67. Indirect Channel Pros & Cons Table 68. Distributors/Traders/ Dealers List List of Figures Figure 1. Heterozygous Familial Hypercholesterolemia Drug Picture Figure 2. Global Sales Market Share of Heterozygous Familial Hypercholesterolemia Drug by Type in 2019 Figure 3. Gemcabene Calcium Picture Figure 4. MGL-3196 Picture Figure 5. ST-103 Picture Figure 6. Others Picture Figure 7. Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Application in 2018 Figure 8. Clinic Picture Figure 9. Hospital Picture Figure 10. Others Picture Figure 11. Global Heterozygous Familial Hypercholesterolemia Drug Market Status and Outlook (2015-2025) (USD Million) Figure 12. United States Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 13. Canada Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 14. Mexico Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 15. Germany Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 16. France Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 17. UK Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 18. Russia Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 19. Italy Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 20. China Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 21. Japan Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 22. Korea Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 23. India Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 24. Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 25. Australia Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) (USD Million) Figure 26. Brazil Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 27. Egypt Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 28. Saudi Arabia Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 29. South Africa Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 30. Turkey Heterozygous Familial Hypercholesterolemia Drug Revenue (Value) and Growth Rate (2015-2025) Figure 31. Global Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Manufacturer in 2019 Figure 32. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Manufacturer in 2019 Figure 33. Top 3 Heterozygous Familial Hypercholesterolemia Drug Manufacturer (Revenue) Market Share in 2019 Figure 34. Top 6 Heterozygous Familial Hypercholesterolemia Drug Manufacturer (Revenue) Market Share in 2019 Figure 35. Key Manufacturer Market Share Trend Figure 36. Global Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 37. Global Heterozygous Familial Hypercholesterolemia Drug Revenue and Growth Rate (2015-2020) (USD Million) Figure 38. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Regions (2015-2020) Figure 39. Global Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Regions in 2018 Figure 40. North America Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) Figure 41. Europe Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) Figure 42. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) Figure 43. South America Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) Figure 44. Middle East & Africa Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) Figure 45. North America Heterozygous Familial Hypercholesterolemia Drug Revenue and Growth Rate (2015-2020) (USD Million) Figure 46. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Countries (2015-2020) Figure 47. North America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Countries in 2018 Figure 48. North America Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Countries (2015-2020) (USD Million) Figure 49. North America Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Countries in 2018 Figure 50. United States Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 51. Canada Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 52. Mexico Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 53. Europe Heterozygous Familial Hypercholesterolemia Drug Revenue and Growth Rate (2015-2020) (USD Million) Figure 54. Europe Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Countries (2015-2020) Figure 55. Europe Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Countries in 2019 Figure 56. Germany Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 57. UK Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 58. France Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 59. Russia Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 60. Italy Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 61. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue and Growth Rate (2015-2020) (USD Million) Figure 62. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Regions 2019 Figure 63. Asia-Pacific Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Regions 2019 Figure 64. China Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 65. Japan Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 66. Korea Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 67. India Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 68. Southeast Asia Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 69. South America Heterozygous Familial Hypercholesterolemia Drug Revenue and Growth Rate (2015-2020) (USD Million) Figure 70. South America Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Countries in 2019 Figure 71. South America Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Countries in 2019 Figure 72. Brazil Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 73. Argentina Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 74. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue and Growth Rate (2015-2020) (USD Million) Figure 75. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Sales Market Share by Countries in 2019 Figure 76. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Countries (2015-2020) Figure 77. Middle East and Africa Heterozygous Familial Hypercholesterolemia Drug Revenue Market Share by Countries in 2019 Figure 78. Saudi Arabia Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 79. Egypt Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 80. Turkey Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 81. South Africa Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2015-2020) (K Pcs) Figure 82. Global Heterozygous Familial Hypercholesterolemia Drug Sales and Growth Rate (2021-2025) (K Pcs) Figure 83. Global Heterozygous Familial Hypercholesterolemia Drug Revenue and Growth Rate (2021-2025) (USD Million) Figure 84. North America Sales Heterozygous Familial Hypercholesterolemia Drug Market Forecast (2021-2025) (K Pcs) Figure 85. Europe Sales Heterozygous Familial Hypercholesterolemia Drug Market Forecast (2021-2025) (K Pcs) Figure 86. Asia-Pacific Sales Heterozygous Familial Hypercholesterolemia Drug Market Forecast (2021-2025) (K Pcs) Figure 87. South America Sales Heterozygous Familial Hypercholesterolemia Drug Market Forecast (2021-2025) (K Pcs) Figure 88. Middle East & Africa Sales Heterozygous Familial Hypercholesterolemia Drug Market Forecast (2021-2025) (K Pcs) Figure 89. Sales Channel: Direct Channel vs Indirect Channel

Daewoong Co Ltd Madrigal Pharmaceuticals Inc Esperion Therapeutics Inc Gemphire Therapeutics Inc